Stock 003020 HEFEI LIFEON PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Hefei Lifeon Pharmaceutical Co., Ltd.

Equities

003020

CNE100004BD9

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-06-03 pm EDT 		5-day change 1st Jan Change
21.35 CNY +0.76% Intraday chart for Hefei Lifeon Pharmaceutical Co., Ltd. +0.52% -8.99%
May. 21 Lifeon Pharmaceutical's Unit Gets Marketing Authorization for Loxoprofen Sodium Oral Solution MT
May. 15 Hefei Lifeon Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023 CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The group's high margin levels account for strong profits.
  • Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
HEFEI LIFEON PHARMACEUTICAL CO., LTD. Stock Hefei Lifeon Pharmaceutical Co., Ltd.
-8.99% 565M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.83% 750B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+34.11% 606B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.70% 356B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.06% 326B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.63% 286B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.02% 246B
B+
NOVARTIS AG Stock Novartis AG
+9.26% 213B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-4.21% 213B
A+
PFIZER, INC. Stock Pfizer, Inc.
+2.43% 167B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 003020 Stock
  4. Ratings Hefei Lifeon Pharmaceutical Co., Ltd.